Biotech Investor’s Comeback: How Alexis Borisy Backed Epstein Associate

The biotech world is witnessing a quiet resurgence of Boris Nikolic, a venture capitalist whose career stalled after his close association with the late Jeffrey Epstein came to light. Once a prominent figure as chief science and technology advisor to Bill Gates, and later as a co-founder of Biomatics Capital Partners, Nikolic’s reputation suffered significantly following the 2019 revelations surrounding Epstein. Now, with backing from a major industry player, he’s launching a new fund and attracting investment, raising questions about the boundaries of rehabilitation in the wake of serious ethical concerns.

The story, first reported by STAT News, centers on Alexis Borisy, a veteran biotech investor and founder of Curie.Bio. Borisy reportedly provided crucial support to Nikolic, helping him establish a new fund that has already secured over $100 million in funding in 2024 and 2025. This support included leveraging the reputation of Curie.Bio to vouch for Nikolic, who then invested in at least one startup within the fund’s portfolio. The move has sparked debate within the industry, with some questioning the appropriateness of rehabilitating a figure so closely linked to Epstein, a convicted sex offender.

A Relationship Under Scrutiny

Nikolic’s connection to Epstein first became public when Epstein named him as a successor executor in his will, just days before his death in federal custody in August 2019. Nikolic publicly stated he was “shocked” and declined the role, but subsequent disclosures revealed a decade-long personal and professional relationship. EpsteinWiki details over 21,000 emails between Nikolic and Epstein, highlighting a sustained connection between the two men. The New York Times and Reuters were among the first to report on Nikolic’s inclusion in Epstein’s will, bringing the relationship into the public eye.

Emails released by the Department of Justice further illustrate the depth of the relationship. In one instance, Epstein reportedly complained to Nikolic about Bill Gates, calling him “cheap” and alleging mistreatment of a former companion. The New York Post reported on these emails in February 2026, adding another layer of complexity to the network of relationships surrounding Epstein.

The Role of Alexis Borisy and Curie.Bio

Borisy’s decision to support Nikolic is particularly noteworthy given the intense scrutiny surrounding Epstein’s associates. Curie.Bio, known for its innovative funding model in the biotech sector, has positioned itself as a forward-thinking investment firm. Borisy’s backing provided Nikolic with a crucial lifeline, enabling him to re-enter the venture capital landscape despite the lingering controversy. STAT News previously profiled Curie.Bio’s funding approach, highlighting Borisy’s influence in the industry.

The extent of Borisy’s involvement remains somewhat opaque. While he reportedly helped Nikolic launch the fund and raise capital, the specific details of the investment structure and the due diligence process have not been publicly disclosed. It’s unclear whether investors in the new fund were fully informed about Nikolic’s past association with Epstein.

Navigating Ethical Considerations in Biotech Investment

This situation raises broader questions about ethical considerations within the biotech investment community. Venture capital firms often prioritize financial returns, but they are also increasingly expected to demonstrate social responsibility. The decision to invest in a fund led by someone with a controversial past forces investors to weigh potential financial gains against reputational risks and ethical concerns. There is no established industry standard for evaluating the backgrounds of fund managers, leaving the decision largely to individual firms and investors.

The case also highlights the challenges of separating individuals from their associations. While Nikolic has not been accused of any wrongdoing related to Epstein’s crimes, his close relationship with the convicted sex offender inevitably raises questions about his judgment and character. The biotech industry, like many others, is grappling with how to balance the principles of second chances with the need to maintain ethical standards.

What Comes Next: Industry Response and Potential Oversight

The industry’s response to Nikolic’s comeback will likely be closely watched. It remains to be seen whether other venture capital firms will follow Borisy’s lead and invest in funds associated with individuals who have faced ethical scrutiny. Increased transparency regarding the backgrounds of fund managers could become a key demand from investors and stakeholders.

Currently, there is limited regulatory oversight of the venture capital industry. While firms are subject to general securities laws, there are no specific rules governing ethical conduct or due diligence requirements. Some advocacy groups are calling for greater scrutiny of the industry, arguing that it has a responsibility to protect investors and uphold ethical standards. However, any significant regulatory changes would likely face strong opposition from the industry itself.

The situation with Boris Nikolic serves as a stark reminder of the enduring consequences of association and the complex ethical dilemmas facing the biotech investment world. As the industry continues to evolve, it will need to grapple with these challenges and develop clear guidelines for navigating the murky waters of reputation, responsibility, and financial gain.